and Milstein (14) . Briefly, splenocytes from unmanipulated 3.5-mo-old IgMRF-positive, MRL/1 mice were mixed with myeloma cells (10:1 ratio; 1 x l0 s spleen cells/1 x 107 myeloma cells) and a 35% final concentration of polyethyleneglycol (PEG 1000; J. T. Baker Chemical Co., Phillipsburg, NJ). After fusion, the cell suspension was mixed with 500 ml of selective HAT-Dulbecco's minimum essential medium (DMEM) supplemented with 10% fetal bovine serum, glutamine, antibiotics, nonessential amino acids, sodium pyruvate, and 4.5 g glucose/liter that contained 2 x 106 fresh BALB/c thymocytes/ml. Subsequently, the cell suspension was distributed in 96-well tissue culture clusters with flat-bottomed wells (3596; Costar, Cambridge, MA). Cultures were placed in humidified 37°C, 5% CO~ incubators and fed after approximately 8 and 14 d with HAT-DMEM containing 5 x 106/ml fresh BALB/c thymocytes. Propagation of hybridomas and subcloning at limiting dilutions were performed as described (15) .
Radioimmunoassayfor RFActivity. The assay for IgMRF has been described (10) . Briefly, polypropylene wells (Dynatech Laboratories, Inc., Alexandria, VA) were coated by desiccation with 50 #1 of a 40 ug/ml polyclonal murine IgG or 40 #g/ml of an equimolar mixture of all murine myeloma IgG subclasses (IgG1, IgG2a, IgG2b, IgG3) in boratebuffered saline (BBS), pH 8.4. After appropriate washes and coating with 200 #1 of BBS containing 2% bovine serum albumin (BSA)-0.05% Tween 80, the wells were incubated overnight at 4°C with 50 #l of appropriately diluted test material. Washed wells were then incubated (4 h, 4°C) with 50 #l of affinity-purified ~SI-labeled (16) F(ab')2 goat antimurine #-specific antibody (200 #g/ml BBS-BSA-Tween 80). Bound radioactivity was counted after a last series of five washes in BBS and specific counts were calculated by subtracting the counts per min associated with wells incubated with control medium. The anti-# serum was made by immunizing a goat with MOPC-104E myeloma (#,X; Litton Bionetics Inc., Kensington, MD) and subsequent affinity purification on a Sepharose 4B-TEPC-183 (#,K; Litton Bionetics Inc.) column. The specifically bound counts of anti-# were referred to a standard curve made by using wells coated with unlabeled anti-# as the first reagent, TEPC-183 (#,K) myeloma diluted in BBS-BSA-Tween 80 at concentrations ranging from 200 to 0.4 #g/ml as the middle reagent, and ~25I-anti-# as the final reagent.
Iglsotypes and lgG Subclasses. Mouse IgM (TEPC-183), IgA (TEPC-15), IgG1 (MOPC-21), IgG2a (UPC10, RPC5), IgG2b , and IgG3 (J606) myelomas were all purchased from Litton Bionetics Inc., whereas murine IgE antidinitrophenyl monoclonal antibody was a gift from Dr. F. T. Liu, Medical Biology Institute, LaJolla, CA. Polyclonal IgG of murine, bovine, rabbit, rat, goat, and human origin were all purchased from Miles Laboratories, Elkhart, IN. Human myeloma IgG subclasses (IgG1, IgG2, IgG3, IgG4) of kappa or lambda light chains and of known Gm allotype composition, and rat IgG subclasses (IgG1, IgG2a, IgG2b, IgG2c) were all a generous gift from Dr. H. Spiegelberg, Scripps Clinic and Research Foundation. Polyclonal murine IgG2a (Igh-1) of a, b, c, d, e, or j allotypes were purified from sera of pertinent murine strains (17) by absorption on staphylococcal protein A-Sepharose CL-4B columns (Pharmacia Fine Chemicals, Uppsala, Sweden) and subsequent elution with 0.1 M citrate/phosphate buffer gradient, pH 3.0-8.0, as described (18) . The above proteins were used either as substrates or inhibitors in the RF radioimmunoassay.
Aggregation of Immunoglobulins.
The various murine myeloma IgG subclasses and homologous and heterologous polyclonal IgG were dissolved in BBS, pH 8.4, at a concentration of 1 mg/ml. They were then heated (63°C or higher) until they became opalescent. The binding of selected mIgMRF to wells coated with an equimolar mixture of murine IgG subclasses (40 #g/ml) was measured in the presence of various concentrations of inhibitor heat-aggregated IgG diluted in BBS-BSA-Tween 80. mIgMRF were diluted to 50% of their maximal binding capacity before testing.
Fab and Fc Fragments. Murine Fab and Fc fragments were prepared as follows. A mixture of polyclonal IgG isolated from BALB/c serum and myeloma IgG2a (UPC-]0) was digested with papain (Worthington Biochemical Co., Freehold, N J) at a 100:1 substrate to enzyme ratio at 37°C for 1 h in 0.15 M phosphate-buffered saline (PBS), pH 7.0, containing 0.002 M EDTA-tetrasodium salt (J. T. Baker Chemical Co.) and 0.02 M Lcysteine (Sigma Chemical Co., St. Louis, MO). The reaction was stopped by the addition of a slight excess of iodoacetamide. Subsequently, the sample was dialyzed against PBS and chromatographed on a Sephadex G-100 (Pharmacia Fine Chemical) column to separate undigested IgG from Fab and Fc fragments. The Fab-and Fc-containing material was then concentrated and passed through a Sepharose CL-4B-staphyiococcal protein A column. The effluent and the 0.1 M citrate buffer (pH 3.5) eluate of this column, containing Fab and Fc, respectively, were dialyzed against PBS, concentrated, and used at 10 #g/ml as substrates in the IgMRF radioimmunoassay.
Human Fc (CH2-CH3 domains, residues 230-446) was obtained as above by papain digestion of a myeloma, IgG1, X (Gmf), except that digestion lasted 18 h instead of the 1 h used for murine IgG2a. Human pFc' (CH3 domain, residues 335-446) was obtained by plasmin (Sigma Chemical Co.) digestion of the above myeloma protein and subsequent chromatographies as detailed elsewhere (19, 20) so as to separate the large Fabc fragment that contains all but the terminal CH3 domain from the small molecular weight fragment consisting of the free CH3 domain.
Staphylococcal Protein A. Protein A purchased from Sigma Chemical Co. as lyophilized powder was dissolved in PBS and used to localize the Fc region that mlgMRF recognized. Microtiter wells were coated with the murine myeloma 19001, reacted (40C, overnight) with an excess of protein A (250 #g/ml BBS), then washed and incubated with the mlgMRF previously diluted to 50% binding capacity. After incubation, wells were washed, and bound IgM was quantitated with radioiodinated anti-# as described for the RF radioimmunoassay. Controls included wells coated with IgG and then incubated with mlgMRF in the absence of protein A, and wells coated with IgG and then sequentially incubated with mlgMRF, washed, and finally reacted with ~5I-labeled protein A.
Human Clq. Human Clq was prepared as detailed elsewhere (21) . It was used for inhibition studies in which selected mlgMRF (diluted to 50% binding capacity), the substrate mouse IgG, or both were preincubated with an excess amount of Clq and then checked for their ability to interact with each other as assessed by the RF radioimmunoassay.
Cross-reactions of mlgMRF with Non-lgG Molecules. Cross-reactions of mlgMRF with mouse kidney nuclei, single-stranded DNA (ssDNA), and double-stranded DNA (dsDNA) were assessed as described (7) . Reactivity with total calf thymus histones was determined by using an enzyme-linked immunosorbent assay (ELISA) modified from a solid-phase test described by Rubin et al. (22) . Binding to chick collagen II was checked by the solidphase ELISA procedure of Stuart et al. (23) . Binding to a synthetic pentapeptide (L-AIa-D-GIu-L-Lys-D-Ala-o-Ala; kindly prepared by Dr. R. Houghten, Scripps Clinic and Research Foundation), which is identical with that in the peptidoglycan of streptococci (24) , was assessed by inhibition radioimmunoassays in which binding of mlgMRF to substrate Ig was assessed in the presence of increasing amounts of the peptide (500-8 #g/ml).
Results

Murine lgG Subclass and Species Specificity of Serum Polyclonal lgMRF.
Before fusing MRL/1 splenocytes with myeloma cells to develop monoclonal autoantibodies, we randomly selected 20 MRL/i female mice, 3-4 mo of age, and checked their sera for levels and specificities of polyclonal IgMRF for murine IgG subclasses and heterologous IgG (Table I ). All sera tested contained significantly elevated amounts of IgMRF compared with sera of three normal control strains. Serum polyclonal IgMRF reacted with all murine IgG subclasses, but the degree of reactivity varied depending on the substrate subclass; the majority of the sera (19 out of 20) reacted most strongly with mouse IgG2a. In regard to heterologous IgG, extensive cross-reactions with human, cow, rat, rabbit, and goat IgG were noted.
Hybridomas Secreting mlgMRF. Four hybridizations were performed with spleen cells from individual, unmanipulated 3.5-too-old MRL/I mice shown to contain high levels of serum IgMRF of broad specificity (mice 5, 7, 9, and 17, listed in Table I ). At the completion of each hybridization the cells were cloned by limiting dilution in "~2,000 microtiter wells. After 2.5-3.5 wk, hybrids developed in 305, 218, 633, and 567 wells, respectively, for a total of 1,723 hybrids in the four fusions. Of these, 4, 3, 4, and 12 clones or 1.3, 1.4, 0.6, and 2.1%, respectively, secreted IgMRF. Positive clones from these experiments, termed RF1 through RF23, were found to secrete considerable amounts of autoantibody at the time of first testing (Table II) . Poisson distribution analysis indicated that <1% of the postive wells could have contained more than one IgM anti-IgG-secreting clone. Nevertheless, to ensure that our mathematical assumption was correct, we subcloned seven clones and found that all secreted IgMRF in amounts similar to those of the parental clones. Sequential analysis of all positive clones over a period of at least 6 mo has shown stable amounts of autoantibody production.
Isotype Spec~cities of the mlgMRF. Classically, RF bind to IgG and very rarely to other immunoglobulin isotypes (reviewed in reference 25). Affinity-purified IgM from five of the most active clones were radioiodinated and their direct IgG Subclass Specificities of the mlgMRF. The IgG subclass specificities of the 23 monoclonals are listed in Table III . Eight clonotypes were identified, and the majority of the monoclonals reacted either exclusively with IgG2a (seven clones) or with all IgG subclasses equivalently (five clones). Of the remaining monoclonals, three bound to IgG2b only, four to IgG1 :IgG2a:IgG3, one to IgG2a:IgG3, one to IgGl:IgG3, one to IgGl:IgG2a, and one to IgG2b:IgG3. No clone that reacted exclusively with IgG1 or IgG3 was identified, although clonesRF8 and RF2 bound much better to these two subclasses, respectively, than to other subclasses. Similar specificity patterns were observed in competition experiments with a pool of the four murine IgG subclasses used as a substrate and individual aggregated IgG subclasses as inhibitors. Representative inhibition experiments with clone RF8 are depicted in Fig. 1 .
Allotypic Specificit#s ofAnti-IgG2a mlgMRF. Six mIgMRF that bound to IgG2a
only were tested for their allotypic specificities against polyclonal IgG2a isolated from the sera of mice expressing Igh-1 allotype of the a, b, c, d, e, or j alleles (Table IV) . Four monoclonal autoantibodies (RF9, RF13, RF17, RF23) bound to IgG2a of the a, c, and e alleles but not those of the b, d, and j alleles. In contrast, two of these monoclonais showed additional specificities: RF14 also reacted with the b allotype and RF22 reacted with all substrate allotypes. It was noteworthy that Igh-1 antigenic specificities represented in the reactive allotypes were also represented in the nonreactive allotypes and vice versa. The only ug mlgMRF/ml with murine polyclonal IgG as a substrate and heterologous heat-aggregated IgG as competitors. Representative inhibition experiments with RF8 are depicted in Fig. 2 . Five monoclonals cross-reactive with human and rat polyclonal IgG (as well as IgG from other species) and one monoclonai cross-reactive only with polyclonal rat IgG were tested for human and rat IgG subclass and human IgG ailotype specificity (Table VI) . Despite some variability in the degree of binding, the five human and rat IgG cross-reacting monoclonals bound to all human IgG subclasses, albeit in most instances to a lesser extent to IgG1 than to the other human subclasses, irrespective of their allotypes, and to all rat IgG subclasses. In contrast, the rat IgG cross-reacting monoclonal bound to rat IgG1 and IgG2a but not to rat IgG2b and IgG2c.
Ig Subfragment Specificity of mlgMRF. All monoclonals were tested for IgG subfragment specificity using as substrates Fab or Fc derived from BALB/c IgG. With the exception of one monoclonai, only the Fc, and not the Fab, elicited binding (Table VII) mIgMRF. The exception was clone RF15, which bound to both substrates but better to Fc than to Fab. The amounts of IgMRF in each monoclonal, as defined by binding to the myeloma pool versus the isolated Fc, did not match. In most instances, Fc promoted better binding than did the IgG pool, perhaps because of a higher availability of Fc sites in the former. However, some of the monoclonals registered higher values for the pool of four IgG subclasses than for the Fc substrate, apparently reflecting the poorer representation of certain IgG subclasses, such as IgG3, in the Fc preparation (derived from IgG2a and polyclonal IgG) than in the equimolar pool of all four murine IgG subclasses. Examples are clone RF2, with primarily an IgG3 specificity, and clone RF8, with primarily an IgG1 specificity (Table III) , both of which reacted best with the pool presumably more abundant in both subclasses.
Attempts to Define the Fc Antigenic Determinants for mlgMRF.
The globular head of a Clq molecule binds to the CH2 domain of antibody (26, 27) . Moreover, protein A, a constituent of the cell wall of Staphylococcus aureus, binds to the Fc sites on antibody molecules of all murine IgG subclasses, but does not interfere with complement binding (28) . Interaction with an excess of human C lq did not inhibit binding by any of the mIgMRF to substrate IgG (data not shown). Nor * Microtiter wells were coated either with a pool of the four IgG subclasses (40 t~g/ml), Fab (10 ~g/ml), or Fc (10 ug/ml). Numbers indicate ~g IgMRF/ml culture supernatant. * Binding equal to background values. did C lq inhibit this reaction when preincubated with both the mlgMRF and the substrate IgG. Thus, none of our mIgMRF recognized antigenic determinants in or around the Clq binding site at the CH2 domain. In contrast, 12 of the 23 mIgMRF were strongly inhibited (>50%) from binding to substrate IgG when protein A was used as a competitor (Table VIII) . Of the remaining 1 1 monoclonals, 1 (RF7) showed a partial inhibition (38.4%) whereas 10 were inhibited very weakly or not at all. No consistent pattern was observed in regard to the inhibitory ability of protein A and any one murine IgG subclass specificity of the mIgMRF. We conclude that over half of our mIgMRF recognize determinants localized at the IgG CH2-CH3 junction or at sites distant to the junction that might be altered or hidden via conformational changes or contact with the protein A.
To determine which of these two possibilities is more likely, we performed the converse experiment where the IgG substrate was first incubated with the monoclonal autoantibodies and then with radioiodinated protein A. Under these conditions the protein A binding was similar to that seen in control wells where the substrate IgG had not been preincubated with the mIgMRF, i.e., no inhibition was observed. Thus, we conclude that the actual binding site for this type of mIgMRF is not localized at the CH2-CH3 junction but at distant sites at the Among the monoclonals not inhibited o r weakly inhibitable by protein A were the five autoantibodies that cross-reacted extensively with all murine IgG subclasses and with heterologous IgG. To localize the antigenic determinant involved in the induction of this type of autoantibody, we examined their ability to interact with Fc (CH2-CH3) or pFc' (CH3 domain) of human IgG1. All five monoclonals bound equally well to the two substrates (data not shown), strongly suggesting that the binding site for these monoclonals is at the CH3 domain.
Cross-reactions of mlgMRF with Non-lgG Substances. None of the 23 mIgMRF
cross-reacted with dsDNA, chick collagen, or synthetic pentapeptide L-AIa-oGIu-L-Lys-D-Ala-D-Aia. However, five of the mIgMRF (clone RF7, RF8, RF18, RF20, RF21) cross-reacted with ssDNA and two of the mIgMRF (clone RF7 and RF 16) showed strong cross-reactions with total calf thymus histories and bound to mouse kidney nuclei. The detailed fine specificities of these six mIgMRF will be described in a separate report. 2 Discussion This is the first report of mlgMRF derived from the polyclonal pool of IgMRFproducing cells that arise spontaneously in MRL/I mice. Others have used similar methods to obtain monoclonal autoantibodies against erythrocytes (29) , DNA (30) , RNA (31) , and Sm (32) from spontaneous murine models of lupus.
Spontaneously occurring monoclonal anti-y-globulins are frequently found in sera of patients with Waldenstrom's macroglobulinemia (5, 6). Kunkel and coworkers (1-4) were the first to divide such mRF into two main groups on the basis of their heavy and light chain variable region subgroups and cross-reacting idiotypes. Subsequently, these (33) and other investigators (34, 35) demonstrated share idiotypic determinants between certain of these mRF and some polyclonal RF associated with RA. Thus, these RF have proven extremely useful in defining the amino acid composition and the biochemical and idiotypic repertoires of human anti-y-globulins, but their quantities are limited. Other mlgMRF (36) were the products of myeloma cells fused with splenocytes of 129/Sv mice preinjected with lipopolysaccharide (LPS), a polyclonal B cell activator. Still another mlgMRF originated from B cells of an individual with RA after in vitro stimulation with Epstein-Barr virus (37) . Although such mitogen-induced autoantibodies and monoclonals therefrom are useful reagents, they may not represent naturally occurring and disease-associated autoantibodies. For example, spontaneously expressed RF in certain colonies of 129/Sv mice are IgA or IgM anti-IgG2a Fc (38, 39) . In contrast, mlgMRF from such animals injected with LPS were almost exclusively of the IgM anti-IgG 1 Fv type (36) . Thus, for analysis of the fine epitopic specificities and of clonotypic and idiotypic characteristics of autoantibodies, monoclonals derived from the pool of spontaneously autoantibody-secreting cells in animals with the relevant disease might be superior to those induced by exogenous polyclonal stimuli.
In a similar fashion to what has been described for human RF (40-42), polyclonal RF in sera of MRL/I mice reacted broadly with all murine IgG subclasses and heterologous IgG, but in most instances, reactivity was stronger with murine IgG2a. Similarly, the majority of our mlgMRF had specificity for IgG2a, exclusive or in association with other murine IgG subclasses. Since immune complexes appear to play a primary role in the induction of RF (43) (44) (45) , one might suggest that the high expression ofanti-IgG2a RF in MRL/I mice is caused by a larger representation of IgG2a in the immune complexes that are abundantly present in sera of such mice. Indeed, most autoantibodies (anti-DNA, anti-gp70, anti-Sm) in these mice are predominantly or exclusively of the IgG2a subclass (46) 3 and the majority of their circulating immune complexes contain IgG2a as the antibody. If RF are indeed directed against antibodies complexed with antigen, they may act as enhancing antibodies similar to those described by Nemazee and Sato (47) that increase production of non-RF autoantibodies.
All our monoclonals with anti-IgG2a or anti-IgG2b activity failed to crossreact with other murine IgG subclasses or heterologous IgG. Similarly, one mlgMRF described by van Snick and Coulie (36) that exhibited anti-IgG2a activity failed to cross-react, unlike their many cross-reactive anti-IgG1 mRF. Moreover, spontaneous polyclonal RF of 129/Sv mice were exclusively antiIgG2a without cross-reactivity with other murine IgG subclasses or heterologous IgG (38, 39) . This lack of cross-reactivity by anti-IgG2a autoantibodies counters the extensive structural homologies (65%) among various murine IgG subclasses and between murine and human subclasses (48, 49) . Thus, our mIgMRF of antiIgG2a or anti-IgG2b type seem to be directed against amino acid sequences or conformational determinants that are exposed uniquely in the aggregated forms of these murine IgG subclasses. Reviewing the sequence characteristics of the aligned CH2 and CH3 domains of the reactive IgG2a and, for example, the nonreactive mouse IgG1 (50), one finds that these two subclasses differ at amino acid residue portions 229-235, 241-254, and 287-294 of the CH2 and 357-372, 381-391, and 416-429 of the CH3 domain. Of these six portions, residues 287-294, 357-372, and particularly 416-429, which are rich in hydrophilic amino acids (iysine, arginine, aspartic acid, and glutamic acid) are more likely to be exposed at the outer surface of the folded IgG2a moleule and, therefore, more likely to stimulate RF production after their complexing with antigen. Obviously, antigenic determinants for the above mIgMRF cannot be defined accurately until the respective peptides have been synthesized and appropriately tested.
When we examined our anti-IgG2a mIgMRF for allotypic specificities, we found that the majority of them reacted with a, c, and e but not b, d, and j allotypes. Similarly, polyclonal RF of 129/Sv mice and mIgMRF from fused cells of LPS-injected 129/Sv mice were restricted in their Igh-1 allotypic specificities (36, 38) . Gm (allotypic) genetic antigens of the human IgG constant homology regions of the heavy chains are often involved in human RF reactions, and several such antigens were first identified by using anti-Gm antibodies from patients with RA (51, 52) . Certain allotypes are also associated with some autoimmune diseases of humans, including systemic lupus erythematosus and RA (reviewed in reference 53). Moreover, a gene linked to the Igh-C locus controls the levels and quality of RF production in some mice (54) . In reviewing the known antigenic specificities of the allotypes used as substrates in our study, none can be singled out as the target determinant, since specificities in reactive allotypes also appear in the nonreactive allotypes and vice versa. On this basis, one can speculate that our anti-IgG2a monoclonals react with a new, as yet undefined, antigenic specificity. However, the known atigenic specificities of IgG2a allotypes have been defined with polyclonal homologous or heterologous antiallotypic antibodies. Therefore, the monoclonal anti-IgG2a autoantibodies could react with a subregion of a known specificity that the polyclonal antiallotypic serum does not distinguish.
In contrast to the restricted anti-IgG2a and anti-IgG2b mIgMRF, monoclonal autoantibodies reacting with all murine IgG subclasses cross-reacted with all heterologous IgG without preference for a given human IgG subclass or allotype. These results indicate that broadly cross-reacting anti-"r-globulins recognize an antigenic determinant that has been highly conserved phylogenetically.
In direct binding assays, all but one of the monoclonal autoantibodies bound to the Fc but not to the Fab portion of mouse IgG, conclusively demonstrating that these monoclonals had the sine qua non qualities of RF. The one exception was monoclonal RF15, which bound to both Fab and Fc, suggesting the presence of a common antigenic determinant in Fab and Fc. In contrast to our mIgMRF derived from the natural repertoire of the MRL/! IgMRF, 48 mIgMRF from LPS-injected 129/Sv mice (36) did not bind to Fab or Fc, theoretically because these monocionals were directed against the Fv region of mouse IgG. This is an unusual characteristic for RF and contrasts with the specificity for Fc of spontaneous polyclonal RF from 129/Sv mice described by the same authors (38, 39) . These findings further support our contention that mitogen-induced autoantibodies may differ from natural autoantibodies in isotypic characteristics and also epitopic specificities.
With Fc identified as the fragment against which our mIgMRF were directed, inhibition studies with protein A and Clq were done to more precisely locate the antigenic determinants involved. The C 1 q binds via its globular heads to the CH2 domains of antibodies (26, 27) at the highly conserved amino acid sequences encompassed within residue 316-338 (55) . However, C 1 q did not inhibit interactions of any of the mIgMRF with substrate IgG, thus ruling out this site as a responsible antigenic determinant. This finding indicates that fixation of C 1 q by immune complexes does not interfere with RF binding or vice versa. Yet protein A, which binds to Fc but does not interfere with complement binding (28) , inhibited the interactions of over one-half of our mIgMRF with the substrate IgG. The crystal structure of the complex between fragment B of protein A and Fc fragments indicates that protein A binds at the CH2-CH3 junction (28, 56, 57) . Thus, the antigenic sites for 12 of the 23 mIgMRF that were strongly inhibited by protein A could be placed at or very near the CH2-CH3 junction. However, in the converse experiment, binding of mIgMRF to substrate IgG did not inhibit subsequent binding of protein A to this substrate, indicating that the binding sites for RF and protein A are not identical. Therefore, the antigenic sites for the RF are distant to the junction but become inaccessible as tertiary IgG folding patterns change after protein A binds. Alternatively, IgG Fc sites distant to the junction in both the CH2 and CH3 domains may become sterically blocked by the protruding chains of the bound protein A, as the crystallographic studies of Deisenhofer (57) have strongly suggested. These sites may include the antigenic determinants identified above on the basis of subclass specificity and structural differences between IgG subclasses, but their exact location on the Fc domains cannot be accurately defined at this time. In contrast, the antigenic site for mIgMRF weakly or not inhibited by protein A is at the CH3 domain. This group includes the five monoclonals that reacted broadly with all murine IgG subclasses and various heterologous IgG. That the site for these five monoclonals is at the CH3 domain was demonstrated by their equal binding to human Fc (CH2-CH3) and pFc' (CH3) pieces.
Studies with human polyclonal RF have shown that some of them cross-react with the nucleosomal histone complex or ssDNA (58) . Antihistone reactivity was also described with a Waldenstrom-derived mRF (59) . We found that two of our mIgMRF exhibited cross-reactions with murine IgG subclasses and certain calf thymus bistones. Elution and inhibition studies to be reported 2 showed that the multiple reactivities of each mIgMRF were a property of a single antibody population. Moreover, five mIgMRF reacted with IgG and ssDNA, and one of the five had additional reactivity with histones. The biologic significance of this type of cross-reaction and the relationship, if any, of the antigenic determinants involved in the activities of these peculiar autoantibodies remain unknown. Anticollagen autoantibodies have been described in RA (60) but possible crossreactions of RF with collagen have not been examined. However, none of our mIgMRF reacted with chick collagen II. Finally, Bokisch et al. (24) described 7S RF-like antibodies of restricted molecular heterogeneity in rabbit immunized with streptococcal cell wall peptidoglycan. A defined pentapeptide sequence of peptidoglycan inhibited interactions of such antibodies with IgG Fc. Our studies failed to disclose any reactivity of the mIgMRF with the pentapeptide sequence of peptidoglycan, thus making it unlikely that MRL]l-associated RF form against such bacterial antigens that cross-react with IgG. Further studies of the mIgMRF that are derived from the natural repertoire of the MRL/I mice will allow us to better define their roles in immune responses and in the pathogenesis of arthritis as well as their idiotypic and epitopic specificities.
Summary
MRL/lpr/lpr (MRL/I) mice develop a lupus-like syndrome and a disease histologically and serologically similar to human rheumatoid arthritis. Their sera contain polyclonal IgM rheumatoid factors (RF) reactive with all murine IgG subclasses (frequently strongest with IgG2a) and several heterologous IgG. To examine the repertoire and epitopic specificities of these RF, we fused splenocytes from 3.5-mo-old seropositive MRL/1 mice with appropriate myeloma partners and derived 1,723 hybridomas of which 23 secreted IgMRF.
These monoclonal IgMRF bound to murine IgG only, not to other murine isotypes. Eight murine IgG subclass-specific clonotypes were identified. Most clones reacted with either multiple IgG subclasses or with IgG2a alone. A few clones reacted solely with IgG2b but none reacted exclusively with IgG1 or IgG3. Monoclonal IgMRF with exclusively anti-IgG2a activity exhibited allotypic specificity, reacting, with few exceptions, with a, c, and e, but not b, d, orj IgG2a allotypes. Four clonotypes could be distinguished by cross-reactivity with IgG from species other than mice. Monoclonals possessing activity against several murine subclasses cross-reacted extensively with heterologous IgG, including all human IgG subclasses without allotypic restrictions. Monoclonal IgMRF specific for murine IgG2a or 2b did not cross-react with beterologous IgG. Based on the absence of cross-reactions by IgG2a-specific monoclonal autoantibodies, certain peptides of the IgG CH2 and CH3 domains appear to generate the antigenic determinants of the anti-IgG2a RF in MRL/I mice.
All of the monoclonal RF bound to Fc and, with one exception, not to Fab fragments of murine IgG. Binding of the monoclonal RF to substrate IgG was not inhibited by Clq, thus excluding the Clq-binding site at the CH2 domain as one of the responsible epitopes in the induction of MRL/I RF. mIgMRF could be categorized as strongly, weakly, or noninhibitable by protein A, which interacts with IgG molecules at or near the CH2-CH3 junction. Inhibition appears to be caused by conformational changes and/or steric shielding of certain IgG areas distant from this junction and not by identical binding sites between protein A and RF. Certain of the mlgMRF that were weakly or not at all inhibitable by protein A were found to cross-react equally well with human Fc (CH2-CH3 domains) and pFc' (CH3 domain) fragments, indicating that the binding site for these monoclonals is at the CH3 domain. Monoclonal RF were devoid of anti-double-strand DNA, anticoUagen, or antipeptidoglycan pentapeptide cross-reactivity, but one of the monoclonals cross-reacted with histones, four with singlestrand DNA, and one with both histones and single-strand DNA.
